{
    "Trade/Device Name(s)": [
        "Wondfo Buprenorphine Urine Test"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K130055",
    "Predicate Device Reference 510(k) Number(s)": [
        "K113624"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "January 9, 2013",
    "Summary Letter Received Date": "January 11, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Buprenorphine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Cup",
        "Dip card"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow chromatographic immunoassay",
        "Competitive binding"
    ],
    "Methodologies": [
        "Antigen-antibody immunochemistry"
    ],
    "Submission Type(s)": [
        "Assay",
        "Cup",
        "Dip card"
    ],
    "Document Summary": "FDA 510(k) summary for Wondfo Buprenorphine Urine Test, an OTC immunochromatographic assay for qualitative detection of buprenorphine in urine.",
    "Indications for Use Summary": "Qualitative determination of buprenorphine in human urine at a 10 ng/mL cutoff in dip card and cup formats; intended for over the counter use with preliminary positive results requiring confirmatory testing.",
    "fda_folder": "Toxicology"
}